Chimie physique générale, Biochimie, Biologie moléculaire Jean-Michel SIMON ............................. Economie de la santé ,
Chimie thérapeutique Chimie thérapeutique ,
Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique ,
Chimie organique Biophysique ,
Pharmacie galénique PROFESSEUR ASSOCIE, Biochimie et Biologie ,
77 3.3.1. La première génération de facteurs de croissance plaquettaire, p.77 ,
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, European Journal of Cancer, vol.42, issue.15, pp.2433-53, 2006. ,
DOI : 10.1016/j.ejca.2006.05.002
Eltrombopag in chronic liver disease patients with thrombocytopenia undergoing a elective invasive procedure: results from elevate, a randomized clinical trial ,
Microparticles, thrombosis and cancer. Best practice &research clinical haematology, 22, pp.61-69, 2009. ,
DOI : 10.1016/j.beha.2008.11.002
Clinical update: intravenous iron for anaemia, The Lancet, vol.369, issue.9572, pp.1502-1504, 2007. ,
DOI : 10.1016/S0140-6736(07)60689-8
Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial, Journal of Clinical Oncology, vol.22, issue.7, pp.1301-1307 ,
DOI : 10.1200/JCO.2004.08.119
Toxicit?? pulmonaire du G-CSF??: Revue syst??matique de la litt??rature clinique et exp??rimentale1G-CSF related pulmonary toxicity, R??animation, vol.11, issue.5, pp.326-332 ,
DOI : 10.1016/S1624-0693(02)00252-9
Actualités du métabolisme du fer Revue de médecine interne, pp.307-310 ,
News in brief, Hématologie, vol.7, issue.5, 2001. ,
An??mie inflammatoire??: physiopathologie et prise en charge, La Revue de M??decine Interne, vol.30 ,
DOI : 10.1016/j.revmed.2009.09.013
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma, Journal of Thrombosis and Haemostasis, vol.18, issue.10, pp.1760-1765, 2004. ,
DOI : 10.1097/00005792-199909000-00001
Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: meta-analysis of randomized trials, Lancet, pp.373-1532, 2009. ,
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck, International Journal of Radiation Oncology*Biology*Physics, vol.38, issue.2, pp.285-289, 1997. ,
DOI : 10.1016/S0360-3016(97)00101-6
Antithrombotic Therapy for Venous Thromboembolic Disease, Chest, vol.126, issue.3, pp.401-428, 2004. ,
DOI : 10.1378/chest.126.3_suppl.401S
Long-term dosing of AMG531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura, Blood, vol.106, p.220, 2005. ,
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial, The Lancet, vol.373, issue.9664, pp.641-648, 2009. ,
DOI : 10.1016/S0140-6736(09)60402-5
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF), Journal of Cellular and Molecular Medicine, vol.8, issue.4, pp.777-794, 2005. ,
DOI : 10.1073/pnas.2135406100
inhibiteurs de l'érythropoïèse: de la physiologie à la thérapeutique, Bull. Acad . Natle. Méd, vol.178, pp.793-806, 1994. ,
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia, Blood, vol.112, issue.8, pp.3135-3137, 2008. ,
DOI : 10.1182/blood-2008-04-153783
Epoetin and mortality in patients with cancer. The Lancet, p.287, 2009. ,
High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia, European Journal of Cancer, vol.37, issue.6, p.100, 2001. ,
DOI : 10.1016/S0959-8049(01)80853-4
Régulation cellulaire et moléculaire. EMC Hématologie, pp.13-019, 2008. ,
Thrombosis with erythropoiesis stimulating agents does iron-deficient erythropoiesis play a role? Seminars in Dialysis, pp.210-211, 2008. ,
Prévalence et localisation des cancers lors du diagnostic de thrombose veineuse profonde symptomatique des membres inférieurs. La revue de Médecine interne, pp.25-26, 2008. ,
Place du cancer parmi les facteurs de risque de la maladie thromboembolique veineuse, Pathologie Biologie, vol.56, issue.4, pp.178-183, 2008. ,
DOI : 10.1016/j.patbio.2007.12.008
Radiotherapy and anaemia ??? the clinical experience, Radiotherapy and Oncology, vol.20, pp.35-40, 1991. ,
DOI : 10.1016/0167-8140(91)90184-I
Neutrop??nies constitutionnelles et acquises, EMC - H??matologie, vol.2, issue.3, pp.158-186, 2005. ,
DOI : 10.1016/j.emch.2005.07.002
Neutrop??nies constitutionnelles et acquises, EMC - H??matologie, vol.2, issue.3, pp.158-186, 2005. ,
DOI : 10.1016/j.emch.2005.07.002
Physiopathog??nie de la maladie thromboembolique veineuse au cours du cancer, Pathologie Biologie, vol.56, issue.4, pp.184-194, 2008. ,
DOI : 10.1016/j.patbio.2008.03.003
Iron requirements in erythropoietin therapy, Best Practice & Research Clinical Haematology, vol.18, issue.2 ,
DOI : 10.1016/j.beha.2004.09.005
Traitement de la maladie thromboembolique veineuse chez le canc??reux, Pathologie Biologie, vol.56, issue.4, pp.220-228, 2008. ,
DOI : 10.1016/j.patbio.2008.02.007
Erythropoietin: Physiologic and Pharmacologic Aspects, Experimental Biology and Medicine, vol.216, issue.3, pp.358-369, 1997. ,
DOI : 10.3181/00379727-216-44183
Plaquettes et tumeurs, Hématologie, vol.12, pp.400-411, 2006. ,
Oxygenation predicts radiation response and survival in patients with cervix cancer, Radiotherapy and Oncology, vol.48, issue.2, pp.149-156, 1998. ,
DOI : 10.1016/S0167-8140(98)00044-9
Les neutrop??nies f??briles chimio-induites??: ?? propos de 200??pisodes, Pathologie Biologie, vol.56, issue.3, pp.154-157, 2008. ,
DOI : 10.1016/j.patbio.2007.09.025
Les agonistes du récepteur de la thrombopoïétine : vers une révolution du traitement du purpura thrombopénique immunologique ? La revue de medecine interne, pp.203-205, 2009. ,
Polynucléaires neutrophiles humains. Revue Francaise des Laboratoires, pp.43-51, 2002. ,
DOI : 10.1016/s0338-9898(02)80180-9
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis, Journal of Clinical Pathology, vol.57, issue.10 ,
DOI : 10.1136/jcp.2003.015032
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism, Archives of Internal Medicine, vol.160, issue.6, pp.809-815, 2000. ,
DOI : 10.1001/archinte.160.6.809
Erythropoietin radiation therapy, Bull Cancer, vol.93, issue.5, pp.495-499, 2006. ,
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res, vol.56, pp.4509-4515, 1996. ,
Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers, British Journal of Clinical Pharmacology, vol.59, issue.3, pp.279-284, 1999. ,
DOI : 10.1111/j.1600-0609.1997.tb00972.x
Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo, Blood Cells, Molecules, and Diseases, vol.44, issue.1, pp.1-6 ,
DOI : 10.1016/j.bcmd.2009.09.007
The erythropoietin receptor in normal and cancer tissues, Critical Reviews in Oncology/Hematology, vol.67, issue.1 ,
DOI : 10.1016/j.critrevonc.2008.03.006
Phase ½ study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome (MDS): update including extented treatment, Blood, 2007. ,
Effect of erythropoietin on human tumor growth in xenograft models, Molecular Medicine Reports, vol.2010, issue.3, pp.95-101 ,
Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma, Cancer Treatment Reviews, vol.35, issue.8, pp.738-743, 2009. ,
DOI : 10.1016/j.ctrv.2009.08.002
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial, The Lancet, vol.371, issue.9610, pp.395-403, 2008. ,
DOI : 10.1016/S0140-6736(08)60203-2
La prescription martiale en réanimation aujourd'hui : une enquête de pratique. Annales Fr d'Anesthésie et de Réanimation, pp.909-914 ,
??rythropo????tine (EPO) et an??mie en soins palliatifs chez le patient atteint de cancer, M??decine Palliative : Soins de Support - Accompagnement - ??thique, vol.6, issue.5, pp.274-284, 2007. ,
DOI : 10.1016/S1636-6522(07)92568-4
Erythropoïétine et radiothérapie, Cancer Radiothérapie, vol.2009, pp.1-6, 2578. ,
Granulocyte colony-stimulating factor receptor: Stimulating granulopoiesis and much more, The International Journal of Biochemistry & Cell Biology, vol.41, issue.12, pp.2372-2375, 2009. ,
DOI : 10.1016/j.biocel.2009.08.011
Effect of Thrombopoietin on Proliferation of Blasts from Patients with Myelodysplastic Syndromes, Stem Cells, vol.84, issue.2, pp.112-119, 2000. ,
DOI : 10.1111/j.1365-2141.1982.tb08475.x
Surveillance des traitements anticoagulants chez les patients atteints de cancer, Pathologie Biologie, vol.56, issue.4, pp.239-244, 2008. ,
DOI : 10.1016/j.patbio.2008.02.011
Surveillance des traitements anticoagulants chez les patients atteints de cancer, Pathologie Biologie, vol.56, issue.4, pp.239-244, 2008. ,
DOI : 10.1016/j.patbio.2008.02.011
Long-term outcomes in adults with chronic ITP after splenectomy failure, Blood, vol.104, issue.4, pp.956-960, 2004. ,
DOI : 10.1182/blood-2003-11-3908
Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C, New England Journal of Medicine, vol.357, issue.22, pp.2227-2236, 2007. ,
DOI : 10.1056/NEJMoa073255
Agoniste du récepteur de la thrombopoïétine : Actualités et perspectives ,
anémie et place de l'érythropoïétine, J Pharm Clin, vol.24, pp.11-16, 2005. ,
Place des filtres caves dans le traitement de la maladie thromboembolique veineuse chez les patients canc??reux, Pathologie Biologie, vol.56, issue.4, pp.229-232, 2008. ,
DOI : 10.1016/j.patbio.2008.03.002
Les microparticules circulantes??: r??les physiologiques et implications dans les maladies inflammatoires et thrombotiques, La Revue de M??decine Interne, vol.26, issue.10, pp.791-801, 2005. ,
DOI : 10.1016/j.revmed.2005.03.015
Marqueurs des pathologies thrombotiques, Annales Pharmaceutiques Fran??aises, vol.65, issue.2, pp.75-84, 2007. ,
DOI : 10.1016/S0003-4509(07)90020-6
Les facteurs de croissance h??matopo????tique en canc??rologie thoracique, Revue des Maladies Respiratoires Actualit??s, vol.1, issue.4, pp.314-319 ,
DOI : 10.1016/S1877-1203(09)72500-5
The erythropoietin receptor, Seminars in Oncology, vol.28, pp.19-23, 2001. ,
DOI : 10.1016/S0093-7754(01)90208-8
Epoetin and mortality in patients with cancer. The Lancet, pp.9686-287, 2009. ,
Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck, Radiotherapy and Oncology, vol.41, issue.1, pp.31-39, 1996. ,
DOI : 10.1016/S0167-8140(96)91811-3
Maladie veineuse thromboembolique et cancer. La Revue de médecine interne, pp.313-322, 2006. ,
Etude des effets directs et indirects de l'erythropoïétine dans un modèle ,
Lénograstime (rHuG-CSF glycosylé) ou filgrastime (r-metHuG-CSF) : un choix difficile ? ,
Mircera?? : le premier activateur connu de l?????rythropo????se ?? injection mensuelle, M??decine des Maladies M??taboliques, vol.2, issue.6, p.661, 2008. ,
DOI : 10.1016/S1957-2557(08)74948-4
Maladie thromboembolique veineuse et cancer, La Revue de M??decine Interne, vol.21, issue.3, pp.266-277, 2000. ,
DOI : 10.1016/S0248-8663(00)80046-6
Anticorps antiphospholipides et cancer, Pathologie Biologie, vol.56, issue.4, pp.245-250, 2008. ,
DOI : 10.1016/j.patbio.2008.02.012
The negative impact of anemia on radiotherapy and chemoradiation outcomes, Seminars in Hematology, vol.38, pp.8-15, 2001. ,
DOI : 10.1016/S0037-1963(01)90125-8
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans, Blood, vol.95, issue.9, pp.2983-2989, 2000. ,
Clinical approaches involving Thrombopoietin to schorten the period of thrombocytopenia after high-dose chemotherapy. Transfusion medicine reviews, pp.283-293, 2006. ,
Hypoxia and anemia: effects on tumor biology and treatment resistance, Transfusion Clinique et Biologique, vol.12, issue.1, pp.5-10, 2005. ,
DOI : 10.1016/j.tracli.2004.11.005
De nouvelles perspectives dans le traitement du purpura thrombopénique : les agonistes du récepteur de la thrombopoïétine, Mt, vol.14, pp.96-104, 2008. ,
Pathogenesis of venous thrombosis: a new insight, Cardiovascular Surgery, vol.5, issue.1, pp.6-15, 1997. ,
DOI : 10.1016/S0967-2109(96)00083-X
Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura, Critical Reviews in Oncology/Hematology, vol.77, issue.3, 2010. ,
DOI : 10.1016/j.critrevonc.2010.03.001
Erythropoietin regulates tumour growth of human malignancies, Carcinogenesis, vol.24, issue.6, pp.1021-1029, 2003. ,
DOI : 10.1093/carcin/bgg060
Cours d'hématologie biologique, Faculté de Médecine d'Angers, 2006. ,
Régulation de l'érythropoïèse : applications physiopathologiques en néphrologie. Flammarion médecine sciences Actualités néphrologiques, pp.117-138, 2003. ,